Skip to content

Study · Non-randomized trial · n = 25 · 2003

3 results

Prospective, randomized, multicenter trial on the antiproliferative effect of lanreotide, interferon alfa, and their combination for therapy of metastatic neuroendocrine gastroenteropancreatic tumors--the International Lanreotide and Interferon Alfa Study Group.

Faiss S, Pape UF, Böhmig M, Dörffel Y, Mansmann U, Golder W, Riecken EO, Wiedenmann B

Journal of clinical oncology : official journal of the American Society of Clinical Oncology1 Jul 2003Cited by 309 (Europe PMC)

PMID12860945 (opens in a new tab)DOI10.1200/jco.2003.12.142 (opens in a new tab)PepBankPUB-12860945
Publisher pagePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. 3 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In metastatic neuroendocrine tumor patients, partial tumor remission occurred in one patient receiving lanreotide monotherapy.

    In plain wordsIn metastatic neuroendocrine tumor patients, one patient receiving lanreotide alone had partial tumor remission.

    Peptide
    Lanreotide
    Outcome
    Not applicablePartial tumor remission
    Study

    n = 25

    Outcome group
    Tumor growth · Cancer
    Studied dose
    1 mg three times a day · subcutaneousAs given in this study (human).

    Measurements

    patients with partial tumor remission
    1 patients
    lanreotide arm, 25 patients

    Source sentences

    Summary
    Partial tumor remission was seen in four patients (one patient who received lanreotide, one patient who received interferon alfa, and two patients who received the combination).
    2 context sentences
    Summary · context
    were randomly treated either with lanreotide (1 mg three times a day administered subcutaneously [SC]) or interferon alfa (5 x 106 U three times a week SC) or both.
    Summary · context
    Twenty-five patients were treated with lanreotide, 27 patients were treated with interferon alfa, and 28 patients were treated with the combination.
  2. 02HumanNon-randomized trialEfficacy outcome

    In metastatic neuroendocrine tumor patients, seven patients receiving lanreotide monotherapy had stable disease during 12 months of therapy.

    In plain wordsIn metastatic neuroendocrine tumor patients, seven patients receiving lanreotide alone had stable disease.

    Peptide
    Lanreotide
    Outcome
    Not applicableStable disease
    Study

    n = 25

    Outcome group
    Tumor growth · Cancer
    Studied dose
    1 mg three times a day · subcutaneous · 12 monthsAs given in this study (human).

    Measurements

    patients with stable disease
    7 patients
    lanreotide arm, 25 patients, 12 months of therapy

    Source sentences

    Summary
    During the 12 months of therapy, stable disease was observed in 19 patients (seven patients who received lanreotide, seven patients who received interferon alfa, and five patients who received the combination),
    2 context sentences
    Summary · context
    were randomly treated either with lanreotide (1 mg three times a day administered subcutaneously [SC]) or interferon alfa (5 x 106 U three times a week SC) or both.
    Summary · context
    Twenty-five patients were treated with lanreotide, 27 patients were treated with interferon alfa, and 28 patients were treated with the combination.
  3. 03HumanNon-randomized trialEfficacy outcome

    In metastatic neuroendocrine tumor patients, tumor progression occurred in 14 of 25 patients receiving lanreotide monotherapy during 12 months.

    In plain wordsIn metastatic neuroendocrine tumor patients, 14 of 25 patients receiving lanreotide alone had tumor progression.

    Peptide
    Lanreotide
    Outcome
    Not applicableTumor progression
    Study

    n = 25

    Outcome group
    Tumor growth · Cancer
    Studied dose
    1 mg three times a day · subcutaneous · 12 monthsAs given in this study (human).

    Measurements

    patients with tumor progression
    14 patients
    lanreotide arm, 25 patients, 12 months of therapy

    Source sentences

    Summary
    whereas tumor progression occurred in 14 of 25 patients (lanreotide), 15 of 27 patients (interferon alfa), and 14 of 28 patients (combination).
    3 context sentences
    Summary · context
    During the 12 months of therapy,
    Summary · context
    were randomly treated either with lanreotide (1 mg three times a day administered subcutaneously [SC]) or interferon alfa (5 x 106 U three times a week SC) or both.
    Summary · context
    Twenty-five patients were treated with lanreotide, 27 patients were treated with interferon alfa, and 28 patients were treated with the combination.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:36 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.